Lausanne University Hospital

News and Video Search Results

News coverage

Nature Medicine Highlights Significant Improvement in Hand and Arm Function After Spinal Cord Injury with Use of ONWARD® ARC-EX® Therapy

GlobeNewswire 20 May 2024

ARC Therapy™ shown to be safe and effective in global pivotal trial*90% of participants improved either strength or function of..

ONWARD® Medical Announces Publication of Full Year 2023 Financial Results and Business Update Webcast
GlobeNewswire 11 Apr 2024
Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00
GlobeNewswire 09 Apr 2024
ONWARD® Medical Submits De Novo Application to FDA for its ARC-EX® System
GlobeNewswire 02 Apr 2024
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
GlobeNewswire 27 Mar 2024

0 shares 1 views

You might like

Lausanne University Hospital media coverage

ONWARD® Medical Publishes Prospectus for Listing of New Shares

GlobeNewswire 21 Mar 2024

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER..

ONWARD® Medical Successfully Raises €20 Million in a Capital Increase by Way of an Accelerated Bookbuild Offering and by Way of a Public Offering in France
GlobeNewswire 21 Mar 2024
ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option
GlobeNewswire 20 Mar 2024
ONWARD® Medical Successfully Completes Benchmark Testing on Path to Commercialize ARC-EX® System
GlobeNewswire 18 Mar 2024
ONWARD® Medical Reaffirms Guidance, Shares 2024 Strategic Priorities, and Releases Unaudited Q4 Financial Highlights
GlobeNewswire 15 Mar 2024

Advertisement

More coverage

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

GlobeNewswire 14 Mar 2024

*AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update*

· ACI-24.060 ABATE Phase 2 trial..

ONWARD® Medical Accepted to New US FDA TAP Program for Development of its ARC-BCI™ System
GlobeNewswire 11 Mar 2024
Pharmaceutical and Biotechnology Sector Insights: Comprehensive Analysis of Option and Evaluation Deals (2016-2024)
GlobeNewswire 05 Mar 2024
ONWARD® Medical Awarded 10th Breakthrough Device Designation for Brain-Computer Interface (BCI) from US FDA
GlobeNewswire 29 Feb 2024
KBC Securities Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 10.00 Per Share
GlobeNewswire 09 Feb 2024